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Carbamazepine-induced thrombocytopenic purpura in a child: insights from a genomic 1	
analysis 2	
 3	
To the Editor, 4	
Carbamazepine is an effective anticonvulsant and has a relatively low incidence of adverse 5	
effects, although it occasionally causes hematologic disorders. We herein describe a patient with 6	
carbamazepine-induced thrombocytopenic purpura that was investigated by pharmacological, 7	
immunological and genomic assays. 8	
A 9 years old Caucasian girl was referred to emergency room because of a skin rash to the 9	
lower limbs of three days’ duration. There was no associated fever, sore throat, abdominal pain or 10	
other systemic manifestations. Two weeks before, a diagnosis of symptomatic epilepsy, due to 11	
cortical dysplasia, with partial seizures, was made and she was treated with carbamazepine 20 12	
mg/kg in 2 daily doses. After seven days of treatment carbamazepine plasma level was in the 13	
therapeutic range (8.2 µg/ l). 14	
There was no previous history of drug allergy, bleeding diathesis or family history of 15	
coagulopathy. Physical examination was unremarkable, except for extensive purpura and petechiae 16	
mainly over lower limbs and few elements on upper trunk (Figure 1). The child was in good general 17	
condition, with no pallor, abdominal examination was normal without splenomegaly, blood 18	
pressure was normal. Haematological examination revealed only a platelet count of 43.000/mm3; 19	
coagulation studies were normal. Liver and kidney function tests were within the normal limits. 20	
Urine test did not show red cells or proteins. 21	
Carbamazepine-induced thrombocytopenia was suspected and therapy was switched to a 22	
non-aromatic anticonvulsant (levetiracetam). On the fifth day from drug discontinuation a rapid rise 23	
in platelet count, up to 375.000/mm3 was detected; at this time platelet associated antibodies were 24	
negative and purpura had almost disappeared. 25	
To investigate the molecular mechanism of carbamazepine-induced thrombocytopenia, 26	
pharmacological and genomic assays were performed.  27	
Written informed consent was obtained from the patient and parents. The presence of 28	
carbamazepine-dependent IgG antibodies in serum, reactive with platelets, was tested by 29	
cytofluorimetry [1]. Proliferation of PBMC from patients and control volunteers was measured 30	
using lymphocyte transformation test, using H3-thymidine [2]. HLA genotyping was performed by 31	
sequence-specific oligonucleotide primed PCR and whole genome genotyping by Illumina Infinium 32	
HumanOmniExpressExome BeadChip. Selection of candidate genes and variants involved in 33	
carbamazepine pharmacokinetics and pharmacodynamics was done using the Pharmacogenomics 34	
Knowledge Base (PharmGKB): in particular, 52 SNPs in 22 genes are listed in this pathway and, of 35	
these, our platform allowed to genotype 29 SNPs in 19 genes. Genotyping of CNVs was done by 36	
the software PennCNV [3]. 37	
Two months after the thrombocytopenic event, the presence of drug-dependent antibodies, 38	
able to bind platelets in the presence of carbamazepine or epoxy-carbamazepine, was tested in 39	
patient’s serum; the antibodies test was performed using normal platelets and incubating them in the 40	
absence or presence of carbamazepine or epoxy-carbamazepine and resulted negative for patient’s 41	
serum. At the same time, no proliferation could be observed on patient’s PBMC after in vitro 42	
treatment with increasing concentrations of carbamazepine. 43	
HLA genotyping identified HLA-A*02:05/*24:02, HLA-B*18:01/*50:01 and HLA-44	
C*06:02/*07:01 alleles. Genotyping of SNPs in carbamazepine pharmacokinetic and 45	
pharmacodynamic pathways did not display any homozygous variant for candidate causative 46	
polymorphisms (Supplementary Table 1). Three chromosome regions with CNVs were identified 47	
(Table 1). Four genes are located in these regions: CSMD1 (chromosome 8: 4480667 – 4484362), 48	
HSD17B2 (chromosome 16: 82027399 – 82169385), MPHOSPH6 (chromosome 16: 82027399 – 49	
82169385) and FOXC2-AS1 (chromosome 16: 86583894 – 86566042). 50	
Carbamazepine occasionally causes hematologic disorders such as aplastic anaemia, 51	
thrombocytopenia and leukopenia. Thrombocytopenia is distinctly uncommon and most often 52	
develops 2 weeks after initiation of treatment and recovers within 1 week after drug discontinuation 53	
[4]. In our patient, thrombocytopenia started within 14 days of carbamazepine initiation and 54	
recovery in platelets counts occurred within 96 hours since drug withdrawal. The pathophysiologic 55	
mechanism remains unknown and is believed to be immune related, with the development of drug-56	
dependent antibodies to platelets and secondary platelet destruction. The most commonly targeted 57	
platelet membrane epitopes are glycoproteins complexes on platelet surface [5]. Once established, 58	
drug sensitivity probably persists indefinitely and patients should be advised to avoid permanently 59	
the medication and other aromatic anti-epileptic drug because of cross-sensitivity.  60	
Our patient did not display drug-dependent antibodies nor an activation of PBMCs in the 61	
presence of carbamazepine, therefore a direct immunological mechanism could not be recapitulated 62	
in vitro. Genetic analysis could not identify in this patient an HLA allele or variant in the 63	
pharmacokinetic and pharmacodynamic pathways that could predispose to the adverse drug reaction 64	
observed, especially for important polymorphisms such as those of epoxide hydroxylases [2]. 65	
Interesting insights were however obtained by analysis of CNVs in patient’s DNA. The largest and 66	
most significant CNV was a 142 kDa fragment elided heterozygously: this alteration affected two 67	
genes encoding for HSD17B2 and MPHOSPH6, leading to the full heterozygous loss of both genes. 68	
HSD17B2 is an enzyme capable of catalysing the interconversion of testosterone and 69	
androstenedione, as well as estradiol and estrone. Interestingly CYP3A4- and CYP3A7-mediated 70	
carbamazepine 10,11-epoxidation is activated by differential endogenous steroids [6] and therefore 71	
a reduction in the activity of HSD17B2 could modify the patterns of carbamazepine 72	
biotransformation, predisposing the patient to the adverse effect observed. MPHOSPH6 is an RNA-73	
binding protein that associates with the RNA-exosome complex and is also involved in the response 74	
to chemicals, steroids and oxidative stress [7]. A 2 kDa heterozygous deletion was present in 75	
chromosome 16 and should lead to the reduction of FOXC2-AS1, an RNA gene that is affiliated 76	
with the non-coding RNA class. Another CNV (3 kDa) was detected in an intron of CSMD1: the 77	
large membrane protein encoded by this gene is known to be modulated by PACSIN2, a protein 78	
important for the demarcation membrane system in megakaryocytes and platelet production [8]. 79	
Therefore, a contribution of the CNV in CSMD1 to the pathogenesis of carbamazepine-induced 80	
thrombocytopenia observed in our patient could be considered. 81	
Previous studies demonstrated that the incidence of drug-induced thrombocytopenia is 82	
affected by genetic variants of various genes, such as ITPA for ribavirin [9] or TDAG8 and HLA-83	
DRA for heparin [10], however these are likely not involved in the pathogenesis of carbamazepine-84	
induced thrombocytopenia. 85	
In summary, although carbamazepine-induced thrombocytopenic purpura appears to be a 86	
rare phenomenon, clinicians should be aware of this potential serious adverse effect and consider 87	
regular complete blood cell counts, especially in the first few weeks following treatment initiation. 88	
Moreover, this study demonstrates that carbamazepine thrombocytopenia can occur even in the 89	
absence of detectable drug-dependent antibodies and with no causative genetic variant in the 90	
pharmacokinetic and pharmacodynamic pathways. Finally, this report illustrates that CNVs analysis 91	
provides interesting insights on patient-specific genetic features that might be involved in the 92	
molecular mechanism predisposing to carbamazepine-induced thrombocytopenia, confirming that 93	
CNVs effect on drug response is relevant but still overlooked. 94	
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Figure 1: evidence of thrombocytopenic purpura on patients’ skin. A. few petechial elements on upper trunk; 181	
B. petechial on volar surface of the foot; C. petechiae on lower limbs 182	
 183	
